Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Andrés Cervantes, ESMO President, is pleased to announce the name of the ESMO President 2027-2028. Thank you to all who voted.
What are the early safety and activity profiles of a first-in-class PD-1/IL-2 bispecific in patients with solid tumours?
A unique opportunity to explore the ESMO Guidelines in the context of real-world cases and have your questions answered by a panel of expert oncologists
See you in Florence to network and share ideas at this dedicated event for the gynae cancers community
Internationally renowned experts invite you to submit your abstract for MAP 2024. This exclusive global congress, taking place from 16 to 18 October 2024 in London, UK, is focused on precision oncology and translational research.
Discover the latest in GI cancer patient management in Munich, June 26-29, or join us online.
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Watch the recent ESMO Deep Dive: Breast Cancer webinar, available to all ESMO members to gain deeper understanding on breakthroughs in Personalised, Molecularly Informed Risk Prediction, Screening and Early Detection.
Online application is now open until 16 Jul 2024
Online application is now open!
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
ESMO Director of Public Policy, Professor Jean-Yves Blay, speaks to leading media outlet Euractiv ahead of the EU 2024 elections about the role of oncologists in delivering Europe’s Beating Cancer Plan during the new EU mandate and the upcoming Hungarian EU Presidency
Findings from the NETTER-2 study
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Findings from the NICHE-2 study
Evidence for efficacy is based on the results from the TRANSCEND-MCL study
Findings from NADINA study
New indications concern the treatment of patients with locally advanced or metastatic NSCLC
Findings from the LAURA study
Findings from the NETTER-2 study
Findings from the NICHE-2 study
Evidence for efficacy is based on the results from the TRANSCEND-MCL study
Findings from NADINA study
New indications concern the treatment of patients with locally advanced or metastatic NSCLC
Findings from the LAURA study
Findings from a pre-specified translational analysis of the MITO END-3 study
Overall survival results from the IMpassion132 study
Evidence for efficacy is based on the results from the TRANSCEND-FL study
The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours
Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours
A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers
Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor
Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Netherlands
Italy
Germany
Switzerland
Germany
Switzerland
Spain
Portugal
Portugal
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
